Droplet digital <scp>PCR</scp> for <scp>BCR</scp>/<scp>ABL</scp>(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression

Wang, Wenjun; Zheng, Chunhua; Liu, Zhuang; Tan, Yanhong; Chen, Xiuhua; Zhao, Bichun; Li, Guoxia; Xu, Zhifang; Ren, Fanggang; Zhang, Yaofang; Chang, Jianmei; Wang, Hongwei

doi:10.1111/ejh.13084

Cited by 36 publications

(26 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The addition of pre-amplification to r-qPCR and dPCR showed a two-three log improvement compared to conventional qPCR, and 24 of 32 samples negative with qPCR resulted positive with r-qPCR and/or dPCR [10]. These preliminary data were subsequently confirmed by other reports [12,96,97]. In particular, Wang and colleagues tested 10 CML patients in FU with a MR4.5, and ddPCR revealed positivity three months earlier than by qPCR in four patients.…”

Section: Dpcr For Mrd Monitoringmentioning

confidence: 74%

“…In particular, Wang and colleagues tested 10 CML patients in FU with a MR4.5, and ddPCR revealed positivity three months earlier than by qPCR in four patients. Therefore, ddPCR seems to be more sensitive than qPCR, allowing better conversion of ddPCR results into International Standard qPCR data, to achieve a deeper molecular biology-based stratification of BCR-ABL1 MRD [96].…”

Section: Dpcr For Mrd Monitoringmentioning

confidence: 99%

See 1 more Smart Citation

Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies

Coccaro

Tota

Anelli

et al. 2020

IJMS

View full text Add to dashboard Cite

The digital polymerase chain reaction (dPCR) is considered to be the third-generation polymerase chain reaction (PCR), as it yields direct, absolute and precise measures of target sequences. dPCR has proven particularly useful for the accurate detection and quantification of low-abundance nucleic acids, highlighting its advantages in cancer diagnosis and in predicting recurrence and monitoring minimal residual disease, mostly coupled with next generation sequencing. In the last few years, a series of studies have employed dPCR for the analysis of hematologic malignancies. In this review, we will summarize these findings, attempting to focus on the potential future perspectives of the application of this promising technology.

show abstract

Section: Dpcr For Mrd Monitoringmentioning

confidence: 74%

Section: Dpcr For Mrd Monitoringmentioning

confidence: 99%

Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies

Coccaro

Tota

Anelli

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…To overcome these limitations, recent emerging technologies, such as next-generation sequencing, next-generation flow, and ddPCR, have been applied for precision medicine (23,24). Among these, ddPCR is an advanced method with results that strongly correlate with those of qRT-PCR (25,26). ddPCR enables the measurement of absolute copy numbers without requiring a reference standard curve (9,10,27).…”

Section: Discussionmentioning

confidence: 99%

“…Because of these advantages, ddPCR has been used to evaluate circulating tumor DNA, mutations, and tumor burden in cancer research (28). ddPCR has also been used to detect MRD and predict prognosis in hematologic malignancy (9,25). Therefore, ddPCR could be an optimal alternative modality for qRT-PCR; however, disadvantages of ddPCR, including its high cost, timeintensiveness, and limited data in the clinical setting, must be solved to allow its wider use (29).…”

Section: Discussionmentioning

confidence: 99%

Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study

Park

Shin

Kim

et al. 2019

In Vivo

View full text Add to dashboard Cite

Background/Aim: Droplet digital polymerase chain reaction (ddPCR) is an exact method of measuring nucleic acids. The aim of this prospective study was to evaluate minimal residual disease (MRD) using ddPCR in chronic myeloid leukemia (CML) patients. Patients and Methods: Between May 2013 and November 2014, CML patients treated with nilotinib were enrolled in our study. BCR/ABL1 transcripts levels were evaluated using ddPCR at the first time of complete molecular response (CMR). We enrolled 15 patients from 7 Institutions. The treatment period and median follow-up period were 45 months and 47 months, respectively. Results: Patients with a high level of BCR/ABL1 transcript had a greater tendency to lose the CMR during the follow-up period (p=0.095). In addition, patients with a low level of BCR/ABL1 transcript showed a longer duration of CMR compared to those with a high level (p=0.032). Conclusion: We found that ddPCR is a sensitive method for detecting MRD and that MRD could affect the duration of the treatment response. Chronic myeloid leukemia (CML) is cytogenetically characterized by the translocation of t(9; 22) (q34;q11.2), which produces the BCR/ABL1 fusion oncogene (1). Since the success of imatinib, the first targeted agent in human history, more effective tyrosine kinase inhibitors (TKIs), such as dasatinib and nilotinib have been introduced to the frontline treatment of CML and show a 76-82% major molecular response rate (2, 3). CML is now thought to be a lifelong disease with a 5-year overall survival rate>90% (4). Previous reports have demonstrated that achievement of an early molecular response is a strong predictive marker of improved outcomes (5). Therefore, the European LeukemiaNet 2273 This article is freely accessible online.

show abstract

“…Actually, more progresses have been achieved by dPCR for MRD evaluation in other hematological malignancies. For instance, in chronic myeloid leukemia, dPCR has been largely shown to be more accurate at low transcript levels compared to standard qPCR [ 48 , 49 , 50 , 51 , 52 ].…”

Section: Digital Pcr For Mrd Monitoringmentioning

confidence: 99%

New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies

Dogliotti

Drandi

Genuardi

et al. 2018

JCM

View full text Add to dashboard Cite

The clearance of malignant clonal cells significantly correlates with clinical outcomes in many hematologic malignancies. Accurate and high throughput tools for minimal residual disease (MRD) detection are needed to overcome some drawbacks of standard molecular techniques; such novel tools have allowed for higher sensitivity analyses and more precise stratification of patients, based on molecular response to therapy. In this review, we depict the recently introduced digital PCR and next-generation sequencing technologies, describing their current application for MRD monitoring in lymphoproliferative disorders. Moreover, we illustrate the feasibility of these new technologies to test less invasive and more patient-friendly tissues sources, such as “liquid biopsy”.

show abstract

Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression

Cited by 36 publications

References 24 publications

Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies

Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies

Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study

New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies

Contact Info

Product

Resources

About